Assessing Mortality Models in Systemic Sclerosis-Related Interstitial Lung Disease

被引:23
|
作者
Mango, Robert L. [1 ]
Matteson, Eric L. [1 ,2 ]
Crowson, Cynthia S. [1 ,2 ]
Ryu, Jay H. [3 ]
Makol, Ashima [1 ,4 ]
机构
[1] Mayo Clin Coll Med & Sci, Div Rheumatol, Rochester, MN 55905 USA
[2] Mayo Clin Coll Med & Sci, Dept Hlth Sci Res, Rochester, MN USA
[3] Mayo Clin Coll Med & Sci, Div Pulm & Crit Care Med, Rochester, MN USA
[4] Mayo Clin, Dept Internal Med, Div Rheumatol, 200 1st St SW, Rochester, MN 55905 USA
基金
美国国家卫生研究院;
关键词
Systemic sclerosis; Interstitial lung disease; Non-specific interstitial pneumonia; Usual interstitial pneumonia; Mortality modeling; IDIOPATHIC PULMONARY-FIBROSIS; SCLERODERMA LUNG; RISK PREDICTION; STAGING SYSTEM; SURVIVAL; TRIALS; SMOKING; PLACEBO; TRENDS; COHORT;
D O I
10.1007/s00408-018-0126-6
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The gender, age, and lung physiology (GAP) model, interstitial lung diseases-GAP (ILD-GAP) model, and the smoking history, age, and diffusion capacity of the lung (SADL) model were compared using a systemic sclerosis-ILD (SSc-ILD) cohort to evaluate which best determined prognosis. The models were applied to a cohort of 179 patients with SSc seen at a tertiary care center within 1 year of ILD diagnosis. Demographics, clinical characteristics, and mortality were recorded. The performance of the models was assessed using standardized mortality ratios (SMR) of observed versus predicted outcomes for calibration and concordance (c)-statistics for discrimination. SSc-ILD patients with usual interstitial pneumonia (31, 17%) had a higher mortality than those with non-specific interstitial pneumonia (147, 83%) (hazard ratio 2.27; 95%CI 1.03-4.97). All 3 models had comparable discrimination (c = 0.72, 0.72, and 0.71, respectively). Regarding calibration, the ILD-GAP model underestimated mortality (SMR 1.50; 95%CI 1.05-2.14). Calibration was acceptable for SADL (SMR 1.00; 95%CI 0.70-1.44) and GAP (SMR 0.90; 95%CI 0.63-1.29). The SADL model underestimated mortality in Stage I ILD. The ILD-GAP model underestimated mortality, and the SADL model underestimated mortality in certain subgroups. However, the GAP model performed well in this cohort, providing the best prognostic information for SSc-ILD.
引用
收藏
页码:409 / 416
页数:8
相关论文
共 50 条
  • [41] Quantitative computed tomography assessment for systemic sclerosis-related interstitial lung disease: comparison of different methods
    Ufuk, Furkan
    Demirci, Mahmut
    Altinisik, Goksel
    EUROPEAN RADIOLOGY, 2020, 30 (08) : 4369 - 4380
  • [42] Short-Term Lung Function Changes and Predictors of Progressive Systemic Sclerosis-Related Interstitial Lung Disease
    Kaenmuang, Punchalee
    Navasakulpong, Asma
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2020, 83 (04) : 312 - 320
  • [43] Characterization of Incident Interstitial Lung Disease in Late Systemic Sclerosis
    Hoa, Sabrina
    Berger, Claudie
    Lahmek, Nouha
    Larche, Maggie
    Osman, Mohammed
    Choi, May
    Pope, Janet
    Thorne, Carter
    Canadian Scleroderma Res Grp, Marie
    Hudson, Marie
    ARTHRITIS & RHEUMATOLOGY, 2025, : 450 - 457
  • [44] Association of Symptoms of Gastroesophageal Reflux, Esophageal Dilation, and Progression of Systemic Sclerosis-Related Interstitial Lung Disease
    Volkmann, Elizabeth R.
    Tashkin, Donald P.
    Leng, Mei
    Kim, Grace Hyun J.
    Goldin, Jonathan
    Roth, Michael D.
    ARTHRITIS CARE & RESEARCH, 2023, : 1690 - 1697
  • [45] Interstitial lung disease in systemic sclerosis
    Kaloudi, O.
    Miniati, I.
    Alari, S.
    Matucci-Cerinic, M.
    INTERNAL AND EMERGENCY MEDICINE, 2007, 2 (04) : 250 - 255
  • [46] Interstitial Lung Disease in Systemic Sclerosis
    Predrag Ostojic
    Marco Matucci Cerinic
    Richard Silver
    Kristin Highland
    Nemanja Damjanov
    Lung, 2007, 185 : 211 - 220
  • [47] Interstitial lung disease in systemic sclerosis
    Ostojic, Predrag
    Cerinic, Marco Matucci
    Silver, Richard
    Highland, Kristin
    Damjanov, Nemanja
    LUNG, 2007, 185 (04) : 211 - 220
  • [48] Interstitial lung disease in systemic sclerosis
    O. Kaloudi
    I. Miniati
    S. Alari
    M. Matucci-Cerinic
    Internal and Emergency Medicine, 2007, 2 : 250 - 255
  • [49] Interstitial lung disease in systemic sclerosis
    Mouthon, L.
    Berezne, A.
    Brauner, M.
    Kambouchner, M.
    Guillevin, L.
    Valeyre, D.
    REVUE DES MALADIES RESPIRATOIRES, 2007, 24 (08) : 1035 - 1046
  • [50] Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis
    Ma, Xinyu
    Tang, Rui
    Luo, Mei
    Zeng, Zhuotong
    Shi, Yaqian
    Tang, Bingsi
    Xiao, Rong
    CLINICAL RHEUMATOLOGY, 2021, 40 (08) : 3185 - 3193